Trial Profile

Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-lymphocyte (PD1-T) Combined With XELOX and Bevacizumab in the First-line Treatment of Recurrent and Metastatic Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Programmed cell death 1 receptor modulators (Primary) ; Bevacizumab; Capecitabine; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use

28 Jul 2023 Planned number of patients changed from 284 to 198.
28 Jul 2023 Planned End Date changed from 1 Dec 2022 to 1 Aug 2023.
28 Jul 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com